Junshi Biosciences and Coherus Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical Onc

Toripalimab in combination with chemotherapy was associated with significant improvements in PFS and OS compared with chemotherapy alone in patients with advanced NSCLC without EGFR/ALK mutations, regardless

Related Keywords

China ,Helsinki ,Eteläuomen Läi ,Finland ,United States ,Shanghai ,Canada ,Chinese ,Junshi Bioscience ,Pabout Toripalimab ,Marek Ciszewski ,Rosh Dias ,Jodi Sievers ,Junshi Biosciences ,Coherus Biosciences ,Zhi Li ,Exchange Commission On ,Ir Team ,European Commission ,Exchange Commission ,Vp Corporate Communications ,National Reimbursement Drug List ,European Union ,Pr Team ,Chief Medical Officer ,Good Clinical Practice ,Southeast Asia ,Biologics License Application ,Prescription Drug User Fee Act ,Breakthrough Therapy ,Fast Track ,Orphan Drug ,Chinese Academy ,Emergency Use Authorizations ,Private Securities Litigation Reform Act ,Coheru Annual Report ,Junshi ,Iosciences ,Coherus ,Nnounce ,Publication ,Positive ,Results ,Rom ,Choice ,Hase ,Linical ,Trial ,Valuating ,Toripalimab ,Combination ,Chemotherapy ,First ,Line ,Treatment ,Mall ,Fell ,Young ,